Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

SNO 2026 Preview: New Directions in Glioma Care

5 November 2026 · By · Wire by Fusion42

Published

5 November 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at medscape.com →

◆ Verified

Fusion42 · 5 November 2026 · Fusion42 review

The 2026 Society for Neuro-Oncology meeting will showcase advances in glioma treatment using targeted therapies, immunotherapies, and diagnostics such as FET-PET imaging and cell-free DNA biomarkers. There is also a strong focus on improving neurocognitive outcomes and patient quality of life in glioma care.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You need to integrate new glioma diagnostics like FET-PET imaging and cell-free DNA biomarkers into your pipeline now as these tools will soon reshape patient monitoring. Advances focusing on patient cognition and independence will open opportunities beyond treatment development.

◆ Coverage

1 source · 5 Nov 2026

◆ Related on Wire

◆ Topics

Medtechgliomatargeted-therapyimmunotherapydiagnosticspatient-outcomes